Long terminal repeat U3 length polymorphism of human foamy virus.

PubWeight™: 1.04‹?› | Rank: Top 15%

🔗 View Article (PMID 9143272)

Published in Virology on April 14, 1997

Authors

M Schmidt1, O Herchenröder, J Heeney, A Rethwilm

Author Affiliations

1: Institut für Virologie und Immunbiologie, Würzburg, Germany.

Articles citing this

Foamy viruses are unconventional retroviruses. J Virol (1999) 2.71

Human foamy virus reverse transcription that occurs late in the viral replication cycle. J Virol (1997) 2.42

Improved primate foamy virus vectors and packaging constructs. J Virol (2002) 1.65

Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors. J Virol (1998) 1.46

Isolation and characterization of an equine foamy virus. J Virol (2000) 1.30

Persistent zoonotic infection of a human with simian foamy virus in the absence of an intact orf-2 accessory gene. J Virol (1999) 1.09

Cell-type-specific regulation of the two foamy virus promoters. J Virol (2001) 1.00

In vitro fidelity of the prototype primate foamy virus (PFV) RT compared to HIV-1 RT. Virology (2007) 0.93

Noncanonical microRNA (miRNA) biogenesis gives rise to retroviral mimics of lymphoproliferative and immunosuppressive host miRNAs. MBio (2014) 0.92

Evolution of foamy viruses: the most ancient of all retroviruses. Viruses (2013) 0.89

Genetic characterization of simian foamy viruses infecting humans. J Virol (2012) 0.86

Molecular dissection of the prototype foamy virus (PFV) RNA 5'-UTR identifies essential elements of a ribosomal shunt. Nucleic Acids Res (2009) 0.83

N-terminally myristoylated feline foamy virus Gag allows Env-independent budding of sub-viral particles. Viruses (2011) 0.79

Feline foamy virus-based vectors: advantages of an authentic animal model. Viruses (2013) 0.77

Articles by these authors

Nucleotide sequence analysis of the env gene and its flanking regions of the human spumaretrovirus reveals two novel genes. EMBO J (1987) 2.87

Human foamy virus reverse transcription that occurs late in the viral replication cycle. J Virol (1997) 2.42

Nuclear localization of foamy virus Gag precursor protein. J Virol (1994) 2.36

Foamy virus capsids require the cognate envelope protein for particle export. J Virol (1999) 2.30

Programmed cell death in AIDS-related HIV and SIV infections. AIDS Res Hum Retroviruses (1993) 2.29

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med (1999) 2.27

Foamy virus particle formation. J Virol (1998) 2.22

Foamy virus reverse transcriptase is expressed independently from the Gag protein. Proc Natl Acad Sci U S A (1996) 2.22

Markers of foamy virus infections in monkeys, apes, and accidentally infected humans: appropriate testing fails to confirm suspected foamy virus prevalence in humans. AIDS Res Hum Retroviruses (1995) 1.92

The carboxyl terminus of the human foamy virus Gag protein contains separable nucleic acid binding and nuclear transport domains. J Virol (1996) 1.91

Efficient pseudotyping of murine leukemia virus particles with chimeric human foamy virus envelope proteins. J Virol (1997) 1.90

Replicating foamy virus-based vectors directing high level expression of foreign genes. Virology (1995) 1.80

A particle-associated glycoprotein signal peptide essential for virus maturation and infectivity. J Virol (2001) 1.80

A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol (1998) 1.79

Characterization of a human foamy virus 170-kilodalton Env-Bet fusion protein generated by alternative splicing. J Virol (1998) 1.67

Identification of the major immunogenic structural proteins of human foamy virus. J Gen Virol (1990) 1.60

Functional analysis of human foamy virus accessory reading frames. J Virol (1993) 1.59

Carboxy-terminal cleavage of the human foamy virus Gag precursor molecule is an essential step in the viral life cycle. J Virol (1997) 1.57

Sites of simian foamy virus persistence in naturally infected African green monkeys: latent provirus is ubiquitous, whereas viral replication is restricted to the oral mucosa. Virology (1999) 1.48

Progressive encephalopathy and myopathy in transgenic mice expressing human foamy virus genes. Science (1991) 1.46

Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors. J Virol (1998) 1.46

Expression of human foamy virus reverse transcriptase involves a spliced pol mRNA. Virology (1996) 1.41

Reactivity of primate sera to foamy virus Gag and Bet proteins. J Gen Virol (1994) 1.40

Lack of chronic immune activation in HIV-infected chimpanzees correlates with the resistance of T cells to Fas/Apo-1 (CD95)-induced apoptosis and preservation of a T helper 1 phenotype. J Immunol (1997) 1.38

A comparative study of higher primate foamy viruses, including a new virus from a gorilla. Virology (1995) 1.37

Primate foamy virus Pol proteins are imported into the nucleus. J Gen Virol (2000) 1.37

HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine (1994) 1.31

Characterization of a foamy virus isolated from Cercopithecus aethiops lymphoblastoid cells. Med Microbiol Immunol (1983) 1.25

Identification of pol-related gene products of human foamy virus. Virology (1993) 1.25

An evolutionarily conserved positively charged amino acid in the putative membrane-spanning domain of the foamy virus envelope protein controls fusion activity. J Virol (2000) 1.23

Human foamy virus proteins accumulate in neurons and induce multinucleated giant cells in the brain of transgenic mice. Am J Pathol (1993) 1.22

An active foamy virus integrase is required for virus replication. J Gen Virol (1999) 1.21

Nucleotide sequence analysis of a cloned DNA fragment from human cells reveals homology to retrotransposons. Mol Cell Biol (1987) 1.18

Complex effects of deletions in the 5' untranslated region of primate foamy virus on viral gene expression and RNA packaging. J Virol (2000) 1.18

Cells expressing the human foamy virus (HFV) accessory Bet protein are resistant to productive HFV superinfection. Virology (1998) 1.16

Evolution of a simian immunodeficiency virus pathogen. J Virol (1998) 1.15

No evidence of antibody to human foamy virus in widespread human populations. AIDS Res Hum Retroviruses (1996) 1.13

Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment. Virology (2001) 1.12

AIDS vaccine developments. Nature (1992) 1.11

Efficient intracellular retrotransposition of an exogenous primate retrovirus genome. EMBO J (2000) 1.11

Infectious proviral clones of chimpanzee foamy virus (SFVcpz) generated by long PCR reveal close functional relatedness to human foamy virus. Virology (1995) 1.09

Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system. J Med Virol (2001) 1.09

Experimental infection of macaques with HIV-2ben, a novel HIV-2 isolate. AIDS (1990) 1.07

A recombinant HIV-1 virus-like particle vaccine: from concepts to a field study. Antibiot Chemother (1971) (1996) 1.05

Gene transfer using replication-defective human foamy virus vectors. Virology (1997) 1.03

BEL-1 transactivator responsive sequences in the long terminal repeat of human foamy virus. Virology (1993) 1.02

Transcription factor AP-1 modulates the activity of the human foamy virus long terminal repeat. J Virol (1991) 1.00

Mouse model to study the replication of primate foamy viruses. J Gen Virol (1997) 1.00

Search for retrovirus in the chronic fatigue syndrome. J Clin Pathol (1992) 0.97

Expression of human foamy virus is differentially regulated during development in transgenic mice. New Biol (1992) 0.97

Human foamy virus: an underestimated neuropathogen? Brain Pathol (1992) 0.97

Foamy virus vectors for suicide gene therapy. Gene Ther (1997) 0.97

In vitro infection of primary and retrovirus-infected human leukocytes by human foamy virus. J Virol (1996) 0.96

Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection. J Med Primatol (2001) 0.96

Enumeration of lymphokine-secreting cells as a quantitative measure for cellular immune responses in rhesus macaques. J Med Primatol (1995) 0.95

Differences in early virus loads with different phenotypic variants of HIV-1 and SIV(cpz) in chimpanzees. AIDS (2001) 0.95

The interleukin-17 gene of herpesvirus saimiri. J Virol (1998) 0.92

Urinary neopterin concentrations in rhesus monkeys after infection with simian immunodeficiency virus (SIVmac 251). AIDS (1989) 0.92

Alterations of thymus cortical epithelium and interdigitating dendritic cells but no increase of thymocyte cell death in the early course of simian immunodeficiency virus infection. Am J Pathol (1993) 0.92

Identification of sites that act together to direct dimerization of human foamy virus RNA in vitro. Virology (1997) 0.92

Squamous epithelial proliferative lesions associated with rhesus Epstein-Barr virus in simian immunodeficiency virus-infected rhesus monkeys. J Infect Dis (1995) 0.90

A strategy for cloning infectious molecular clones of retroviruses from serum or plasma. J Virol Methods (2000) 0.90

Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant. J Virol (1997) 0.89

Stimulation of the human RAD51 nucleofilament restricts HIV-1 integration in vitro and in infected cells. J Virol (2011) 0.89

Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine (2001) 0.89

Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Intervirology (1996) 0.88

The therapeutic potential of siRNA in gene therapy of neurodegenerative disorders. J Neural Transm Suppl (2007) 0.87

Mucosal exposure to subinfectious doses of SIV primes gut-associated antibody-secreting cells and T cells: lack of enhancement by nonneutralizing antibody. Virology (2001) 0.87

Relationship between viral load in blood, cerebrospinal fluid, brain tissue and isolated microglia with neurological disease in macaques infected with different strains of SIV. J Neurovirol (2000) 0.87

Fatal myocarditis associated with acute parvovirus B19 and human herpesvirus 6 coinfection. J Clin Microbiol (2001) 0.86

In vitro and in vivo infection of rhesus monkey microglial cells by simian immunodeficiency virus. Virology (1993) 0.86

Specific binding of recombinant foamy virus envelope protein to host cells correlates with susceptibility to infection. Virology (1999) 0.85

Absence of serological evidence for foamy virus infection in patients with amyotrophic lateral sclerosis. J Med Virol (1996) 0.85

Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques. Eur J Immunol (1999) 0.85

T-cell lymphoma caused by herpesvirus saimiri C488 independently of ie14/vsag, a viral gene with superantigen homology. J Virol (1998) 0.84

Regulation of expression and pathogenic potential of human foamy virus in vitro and in transgenic mice. Curr Top Microbiol Immunol (1996) 0.84

vpu and env sequence variability of HIV-1 isolates from Tanzania. AIDS Res Hum Retroviruses (1994) 0.84

Virologic and serologic characteristics of a natural chimpanzee lentivirus infection. Virology (1995) 0.84

Longitudinal comparison of virus load parameters and CD8 T-cell suppressive capacity in two SIVcpz-infected chimpanzees. J Med Primatol (2001) 0.84

Different proliferative response of human and chimpanzee lymphocytes after contact with human immunodeficiency virus type 1 gp120. Eur J Immunol (1994) 0.83

An in vivo model for HIV resistance development. AIDS Res Hum Retroviruses (2001) 0.83

Replication of a foamy virus mutant with a constitutively active U3 promoter and deleted accessory genes. J Gen Virol (1999) 0.83

Genetic variability of the V1 and V2 env domains of SIVcpz-ant and neutralization pattern of plasma viruses in a chimpanzee infected naturally. J Med Virol (2001) 0.83

Characterization of human foamy virus proteins expressed by recombinant vaccinia viruses. AIDS Res Hum Retroviruses (1997) 0.83

Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplantation (2001) 0.82

Analysis of the determinants of neurotropism and neurotoxicity of HFV in transgenic mice. Virology (1996) 0.82

Comparative analysis of apoptosis in HIV-infected humans and chimpanzees: relation with lymphocyte activation. Immunol Lett (1996) 0.82

Foamy virus--adenovirus hybrid vectors. Gene Ther (2004) 0.82

Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys. J Gen Virol (2001) 0.79

Transduction of human neural progenitor cells with foamy virus vectors for differentiation-dependent gene expression. Gene Ther (2008) 0.78

Differential cytotoxic T-lymphocyte (CTL) responses in HIV-1 immunised sibling chimpanzees with shared MHC haplotypes. Immunol Lett (1999) 0.77

Degeneration of the cerebellar granule cell layer in transgenic mice expressing genes of human foamy virus. Neuropathol Appl Neurobiol (1998) 0.77

Effect of vaccination with recombinant modified vaccinia virus Ankara expressing structural and regulatory genes of SIV(macJ5) on the kinetics of SIV replication in cynomolgus monkeys. J Med Primatol (2001) 0.77

The usefulness of a perfect parasite. Gene Ther (2008) 0.77

Improvement of chronic active hepatitis C in chronically infected chimpanzees after therapeutic vaccination with the HCV E1 protein. Acta Gastroenterol Belg (2000) 0.77